A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
Study Details
Study Description
Brief Summary
The purpose of this clinical trial is to learn about the safety, tolerability, Pharmacokinetics (PK), and preliminary efficacy of ARV-471 as monotherapy in Japanese participants with ER+/HER2- locally advanced or metastatic breast cancer (mBC).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ARV-471 Daily oral dosages of ARV-471 |
Drug: ARV-471
ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
|
Outcome Measures
Primary Outcome Measures
- Dose Limited Toxicities (DLTs) [Time Frame: Up to 29 days]
Number of participants with dose-limiting toxicities (DLTs)
Secondary Outcome Measures
- Safety and Tolerability as assessed by adverse event monitoring for participants. [Up to 24 months]
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study therapy.
- Safety and Tolerability through monitoring of laboratory assessments for participants. [Up to 24 months]
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.
- Single Dose: AUC from time zero to time tau (AUCtau) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Single Dose: AUC from time zero to time of last measurable concentration (AUClast) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Single Dose: Maximum Observed Concentration (Cmax) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Single Dose: Time to Maximum concentration (Tmax) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Single Dose: Terminal Elimination half-life (t1/2) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Single Dose: Metabolite Ratio Cmax (MRCmax) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: AUC from time zero to time tau (AUCtau) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: AUC from time zero to time of last measurable concentration (AUClast) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Maximum Observed Concentration (Cmax) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Minimum Observed Concentration (Cmin) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Trough Observed Concentration (Ctrough) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Apparent total clearance (CL/F) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471
- Multiple Dose: Time to Maximum concentration (Tmax) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Apparent volume of distribution (Vz/F) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471
- Multiple Dose: accumulation ratio based on AUC (observed) (Rac) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Terminal Elimination half-life (t1/2) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Effective half-life based on accumulation ratio (t½eff) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Metabolite Ratio Cmax (MRCmax) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Multiple Dose: Metabolite Ratio AUCtau (MRAUCtau) [Up to 24 months]
Pharmacokinetic (PK) assessments for ARV-471 and ARV-473 (an epimer of ARV-471)
- Overall Response Rate (ORR) in participants [Up to 24 months]
- Clinical Benefit Response (CBR) based on the summation of complete Response (CR), Partial Response (PR) and Stable Disease (SD) of 24 weeks duration or longer in participants [Up to 24 months]
- Progression Free Survival (PFS) observed in participants [Up to 24 months]
- Duration of Response (DOR) in participants [Up to 24 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants (women and men) at least 20 years of age at the time of signing the informed consent.
-
Histological or cytological diagnosis of ER+/HER2- advanced breast cancer that is metastatic, recurrent, or locally advanced unresectable breast cancer.
-
Participants who are resistant to standard therapy or for which no standard therapy is available or have received.
-
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Infromed Consent Document (ICD) and in this protocol.
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
-
Adequate Bone Marrow or Coagulation Function.
-
Adequate Renal Function, defined as an estimated creatinine clearance ≥60 mL/min as calculated using the method standard for the institution.
-
Adequate Liver Function.
-
Participants with brain metastases must meet all the specified conditions.
-
Resolution of acute effects of any prior therapy to either baseline severity or CTCAE version 5.0 Grade ≤1.
Exclusion Criteria:
-
Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix, Bowen's disease.
-
Participants sustaining major surgery defined as a complex procedure performed under regional or general anesthesia with a recovery period of at least 4 weeks prior to study enrollment.
-
Known or suspected hypersensitivity or severe allergy to active ingredient/excipients of ARV-471.
-
Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
-
Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to
25% of the bone marrow. Palliative radiation for the alleviation of pain due to bone metastasis will be allowed during the study.
-
Concurrent administration of medications, foods or herbal supplements that are strong inhibitors or inducers of cytochrome CYP3A4, substrates of P-gp, sensitive substrates of CYP2B6, proton pump inhibitors, or medicines known risk of causing Torsade de Pointes. Prior use of strong CYP3A inhibitors must be stopped 7 days and strong CYP3A inducers must be stopped 14 days before randomization.
-
Prior treatment with ARV-471.
-
Systemic anticancer therapy chemotherapy or endocrine therapy within 14 days prior to study entry (6 weeks for mitomycin C or nitrosoureas). If the last immediate anticancer treatment contained an antibody-based agent(s) (approved or investigational), then an interval of 28 days or 5 half-lives (whichever is shorter) of the agent(s) prior to receiving the study intervention treatment is required.
-
Participants who have initiated therapy with bone-modifying agents (bisphosphonates, denosumab, or similar) within 14 days of enrollment.
-
Previous high-dose chemotherapy requiring stem cell rescue.
-
Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry. A participant may be eligible even if they are in the follow-up phase of an investigational study as long as they haven't received treatment in the study for 5 half lives of the agents.
-
Serum pregnancy test (for females of childbearing potential) positive at screening and/or a breastfeeding participant.
-
Participants with active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and known Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)-related illness.
-
Baseline standard 12 lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
-
Any of the following in the previous 12 months: myocardial infarction, long QT syndrome, Torsade de Pointes, clinically important atrial or ventricular arrhythmias, serious conduction system abnormalities, unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF, New York Heart Association class III or IV, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, and/or other clinical significant episode of thrombo-embolic disease. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, atrial fibrillation of any grade . If a participant has a cardiac rhythm device/pacemaker placed and QTcF >470 ms, the participant may be considered eligible. Participants with cardiac rhythm device/pacemaker must be discussed in detail with the sponsor to judge eligibility.
-
History of symptomatic cardiac valve disease.
-
Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Aichi Cancer Center Hospital | Nagoya | Aichi | Japan | 464-8681 |
| 2 | National Cancer Center Hospital East | Kashiwa | Chiba | Japan | 277-8577 |
| 3 | National Cancer Center Hospital | Chuo-ku | Tokyo | Japan | 104-0045 |
Sponsors and Collaborators
- Pfizer
- Arvinas Androgen Receptor, Inc.
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- C4891016